Health Economics›Chronic myelomonocytic leukemia›First-line therapy

First-line therapy

Chronic myelomonocytic leukemia · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Decitabine monotherapy Variant #01	—	R 32 080	42d	—	~10.1 mo	~2	~R 64 160 PFS proxy · indirect	1
Azacitidine and Vorinostat Variant #01 Partial	—	R 29 332	28d	—	—	~2	~R 58 664 indirect	—
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	~24.5 mo	~6	~R 175 992 PFS proxy · indirect	1
Azacitidine and Lenalidomide Variant #01	—	R 23 129	28d	—	—	~7	~R 161 906 indirect	—
Hydroxyurea monotherapy Variant #01	—	R 265	28d	—	~243.6 mo	~2	~R 529 PFS proxy · indirect	—
Decitabine and cedazuridine monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

6 of 6 regimens shown